Choi Jin-Ho, Balasubramanian Ravikumar, Lee Phil H, Shaw Natalie D, Hall Janet E, Plummer Lacey, Buck Cassandra L, Kottler Marie-Laure, Jarzabek Katarzyna, Wołczynski Sławomir, Quinton Richard, Latronico Ana Claudia, Dode Catherine, Ogata Tsutomu, Kim Hyung-Goo, Layman Lawrence C, Gusella James F, Crowley William F
Harvard Reproductive Endocrine Sciences Center and Reproductive Endocrine Unit (J.-H.C., R.B., N.D.S., J.E.H., L.P., C.L.B., W.F.C.), and Department of Medicine, Psychiatric, and Neurodevelopmental Genetics Unit (P.H.L.), Analytic and Translational Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, and Center for Human Genetic Research (J.F.G.), Massachusetts General Hospital, and Department of Genetics, Harvard Medical School, Boston, Massachusetts Boston, Massachusetts 02114; Department of Genetics (M.-L.K.), University Hospital, Caen, 14003, Caen Cedex, France; Department of Biology and Pathology of Human Reproduction in Bialystok (K.J.), Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, and Department of Reproduction and Gynecological Endocrinology (S.W.), Medical University of Bialystok, Sklodowskiej 24A, 15-276 Bialystok, Poland; Institute for Genetic Medicine (R.Q.), Newcastle University, Newcastle-upon-Tyne, NE1 3BZ, United Kingdom; Disciplina de Endocrinologia (A.C.L.), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, 05403-900 Sao Paulo, Brazil; Laboratoire de Biochimie et Génétique Moléculaire (C.D.), Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75014 Paris, France; Departments of Molecular Endocrinology and Pediatrics (T.O.), Hamamatsu University of School of Medicine, Hamamatsu 431-3192, Japan; Section of Reproductive Endocrinology, Infertility, and Genetics (H.-G.K., L.C.L.), Departments of Obstetrics and Gynecology and Neuroscience and Regenerative Medicine, Medical College of Georgia at Georgia Regents University, Augusta, Georgia 30912; and Department of Pediatrics (J.-H.C.), Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea.
J Clin Endocrinol Metab. 2015 Oct;100(10):E1378-85. doi: 10.1210/jc.2015-2262. Epub 2015 Jul 24.
Loss of function (LoF) mutations in more than 20 genes are now known to cause isolated GnRH deficiency (IGD) in humans. Most causal IGD mutations are typically private, ie, limited to a single individual/pedigree. However, somewhat paradoxically, four IGD genes (GNRH1, TAC3, PROKR2, and GNRHR) have been shown to harbor LoF founder mutations that are shared by multiple unrelated individuals. It is not known whether similar founder mutations occur in other IGD genes.
The objective of the study was to determine whether shared deleterious mutations in IGD-associated genes represent founder alleles.
This study was an international collaboration among academic medical centers.
IGD patients with shared mutations, defined as those documented in three or more unrelated probands in 14 IGD-associated genes, were identified from various academic institutions, the Human Gene Mutation Database, and literature reports by other international investigators. Haplotypes of single-nucleotide polymorphisms and short tandem repeats surrounding the mutations were constructed to assess genetic ancestry.
A total of eight founder mutations in five genes, GNRHR (Q106R, R262Q, R139H), TACR3 (W275X), PROKR2 (R85H), FGFR1 (R250Q, G687R), and HS6ST1 (R382W) were identified. Most founder alleles were present at low frequency in the general population. The estimated age of these mutant alleles ranged from 1925 to 5600 years and corresponded to the time of rapid human population expansion.
We have expanded the spectrum of founder alleles associated with IGD to a total of eight founder mutations. In contrast to the approximately 9000-year-old PROKR2 founder allele that may confer a heterozygote advantage, the rest of the founder alleles are relatively more recent in origin, in keeping with the timing of recent human population expansion and any selective heterozygote advantage of these alleles requires further evaluation.
现已发现20多个基因的功能丧失(LoF)突变会导致人类孤立性促性腺激素释放激素缺乏症(IGD)。大多数导致IGD的突变通常是私有的,即仅限于单个个体/家系。然而, somewhat paradoxically,四个IGD基因(GNRH1、TAC3、PROKR2和GNRHR)已被证明存在多个不相关个体共有的LoF奠基者突变。尚不清楚其他IGD基因是否存在类似的奠基者突变。
本研究的目的是确定IGD相关基因中共享的有害突变是否代表奠基者等位基因。
本研究是学术医学中心之间的国际合作。
从各学术机构、人类基因突变数据库以及其他国际研究人员的文献报告中,识别出IGD相关基因中共享突变的患者,这些突变定义为在14个IGD相关基因中的三个或更多不相关先证者中记录的突变。构建突变周围单核苷酸多态性和短串联重复序列的单倍型,以评估遗传谱系。
在五个基因中总共鉴定出八个奠基者突变,分别是GNRHR(Q106R、R262Q、R139H)、TACR3(W275X)、PROKR2(R85H)、FGFR1(R250Q、G687R)和HS6ST1(R382W)。大多数奠基者等位基因在普通人群中以低频率存在。这些突变等位基因的估计年龄在1925年至5600年之间,与人类人口快速扩张的时间相对应。
我们已将与IGD相关的奠基者等位基因谱扩展至总共八个奠基者突变。与可能赋予杂合子优势的约9000年前的PROKR2奠基者等位基因不同,其余奠基者等位基因的起源相对较新,这与近期人类人口扩张的时间一致,这些等位基因的任何选择性杂合子优势都需要进一步评估。